Identification of Molecular Subtypes and a Prognostic Signature Based on m6A/m5C/m1A-Related Genes in Lung adenocarcinoma

Authors:

Abstract
Lung adenocarcinoma (LUAD) is the most common histological type of lung cancer and has high incidence and mortality rates worldwide. Increasing evidence suggests that RNA modifications involving m6A, m5C, and m1A play a vital part in tumorigenesis, drug resistance and immunotherapy. However, there is no reliable model according to m6A/m5C/m1A-related genes to predict the patients’ prognosis in LUAD. We obtained patient data from The Cancer Genome Atlas (TCGA) and captured m6A/m5C/m1A-related genes from the GeneCards database. The “ConsensusClusterPlus” R package was used to generate molecular subtypes based on m6A/m5C/m1A-related genes obtained by differential expression analysis and univariate Cox analysis. We constructed a prognostic signature consisting of six genes (SNHG12, PABPC1, IGF2BP1, FOXM1, CBFA2T3, and CASC8), which was identified as an independent prognostic factor. Higher risk scores were associated with poorer overall survival and increased expression of human leukocyte antigen and immune checkpoints. The relationships between m6A/m5C/m1A regulated gene subsets and risk model and immune cell infiltration were analyzed using estimate, CIBERSORT, TIMER, ssGSEA algorithms and exclusion (TIDE). The tumour stemness indices (TSIs) were also compared based on m6A/m5C/m1A -related molecular subtypes and the risk signature. Based on the risk signature, various analyses were conducted including stratification, somatic mutation, nomogram construction, chemotherapeutic response prediction, and small-molecule drug prediction. In conclusion, we constructed a six-gene prognostic signature that could be useful for prognostication in LUAD patients and designing personalized treatments, which could provide new versions of personalized management for these patients.

This publication has 20 references indexed in Scilit: